Company Description
Carmell Corporation operates as a bio-aesthetics company.
The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks.
The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.
In addition, the company is also developing a line of men’s products and a line of topical haircare products.
It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics.
The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023.
Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2007 |
| Industry | Household & Personal Products |
| Sector | Consumer Staples |
| Employees | 10 |
| CEO | Rajiv Shukla |
Contact Details
Address: 2403 Sidney Street, Suite 300 Pittsburgh, Pennsylvania 15203 United States | |
| Phone | 919 313 9633 |
| Website | carmellcosmetics.com |
Stock Details
| Ticker Symbol | CTCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842939 |
| CUSIP Number | 142922103 |
| ISIN Number | US1429221039 |
| Employer ID | 86-1645738 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kendra Bracken-Ferguson | Chief Executive Officer |
| Rajiv Sarman Shukla | Executive Chairman |
| Bryan J. Cassaday | Chief Financial Officer |
| Dr. Phil Campbell Ph.D. | Founder and Chief Scientific Officer |
| Dr. Lee Weiss Ph.D. | Founder |
| Dr. James Burgess M.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 13, 2025 | 424B3 | Prospectus |
| Feb 12, 2025 | EFFECT | Notice of Effectiveness |
| Feb 10, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 10, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 7, 2025 | SCHEDULE 13G/A | Filing |
| Feb 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 31, 2025 | PRE 14A | Other preliminary proxy statements |
| Jan 29, 2025 | D | Notice of Exempt Offering of Securities |
| Jan 27, 2025 | 424B3 | Prospectus |
| Jan 24, 2025 | 8-K | Current Report |